A primary effect reported by users of antidepressants is emotional numbing, where the full spectrum of feelings is compressed. While this reduces extreme anxiety, it also impairs positive emotions, impacting creativity, relationships, and overall engagement with life—a significant trade-off.

Contrary to popular belief, maximizing dopamine doesn't always enhance sexual function. While dopamine drives desire, excessively high levels create a state of high alert (sympathetic nervous system). This state prevents the engagement of the calming parasympathetic nervous system, which is required for physical arousal, creating a mind-body disconnect.

Doctors are often trained to interpret symptoms arising after stopping psychiatric medication as a relapse of the original condition. However, these are frequently withdrawal symptoms. This common misdiagnosis leads to a cycle of re-prescription and prevents proper discontinuation support.

The advent of SSRIs was a major innovation that moved depression treatment into primary care and reduced stigma. However, this shift had a downside: physicians became less familiar with older, more cumbersome but potent drugs like MAOIs and lithium, narrowing the therapeutic arsenal for tough cases.

The history of depression treatment shows a recurring pattern: a new therapy (from psychoanalysis to Prozac) is overhyped as a cure-all, only for disappointment to set in as its limitations and side effects become clear. This cycle of idealization then devaluation prevents a realistic assessment of a treatment's specific uses and downsides.

SSRIs block serotonin reuptake, but excess serotonin spills over and is absorbed by dopamine transporters. This effectively puts the "negative/waiting" signal (serotonin) into the "positive/reward" pathway. This mechanism may explain the anhedonia, or blunted pleasure, that some patients experience on these medications.

Psychiatric training often instructs doctors to interpret symptoms that arise after stopping medication as a relapse of the original illness. However, these effects are frequently a physiological withdrawal response. This misinterpretation can lead to inappropriate guidance and prolonged medication dependence.

GLP-1 agonists don't just reduce cravings for food; they suppress wanting and desire in general. Because romantic love operates on the same dopaminergic pathways, these 'anti-desire' drugs may significantly diminish a person's capacity to fall in love or maintain romantic feelings in existing relationships.

When patients stop antidepressants, they often experience severe withdrawal symptoms like panic attacks and insomnia. Doctors, trained to look for relapse, frequently misinterpret these as a return of the underlying illness, creating a cycle of unnecessary long-term medication.